View from the heart: Cardiac fibroblasts in development, scarring and regeneration

Development (Cambridge)

Volumn 143, Issue 3, 2016, Pages 387-397

  Furtado, Milena B ^a,c   Nim, Hieu T ^a   Boyd, Sarah E ^a   Rosenthal, Nadia A ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c JACKSON LABORATORY   (United States)

Author keywords

Fibroblasts; Heart; Regeneration; Scarring

Indexed keywords

CARDIAC STEM CELL; GENE EXPRESSION; HEART DEVELOPMENT; HEART FIBROBLAST; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCAR FORMATION; TISSUE REGENERATION; ANIMAL; CYTOLOGY; EMBRYOLOGY; FIBROBLAST; GENE EXPRESSION PROFILING; HEART; PATHOLOGY; REGENERATION; SCAR; STEM CELL;

ANIMALS; CICATRIX; FIBROBLASTS; GENE EXPRESSION PROFILING; HEART; HUMANS; REGENERATION; STEM CELLS;

EID: 84956661487     PISSN: 09501991     EISSN: 14779129     Source Type: Journal    
DOI: 10.1242/dev.120576     Document Type: Review

References (123)

1. Abe, R., Donnelly, S. C., Peng, T., Bucala, R. and Metz, C. N. (2001). Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166, 7556-7562.
2. Acharya, A., Baek, S. T., Huang, G., Eskiocak, B., Goetsch, S., Sung, C. Y., Banfi, S., Sauer, M. F., Olsen, G. S., Duffield, J. S. et al. (2012). The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development 139, 2139-2149.
3. Ahuja, P., Sdek, P. and MacLellan, W. R. (2007). Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol. Rev. 87, 521-544.
4. Ali, S. R., Ranjbarvaziri, S., Talkhabi, M., Zhao, P., Subat, A., Hojjat, A., Kamran, P., Muller, A. M., Volz, K. S., Tang, Z. et al. (2014). Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ. Res. 115, 625-635.
5. Anderson, M. E., Goldhaber, J., Houser, S. R., Puceat, M. and Sussman, M. A. (2014). Embryonic stem cell-derived cardiac myocytes are not ready for human trials. Circ. Res. 115, 335-338.
6. Antos, C. L., McKinsey, T. A., Frey, N., Kutschke, W., McAnally, J., Shelton, J. M., Richardson, J. A., Hill, J. A. and Olson, E. N. (2002). Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 99, 907-912.
7. Armulik, A., Genové, G. and Betsholtz, C. (2011). Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 21, 193-215.
8. Asakura, A. and Rudnicki, M. A. (2002). Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. Exp. Hematol. 30, 1339-1345.
9. Ballermann, B. J. and Obeidat, M. (2014). Tipping the balance from angiogenesis to fibrosis in CKD. Kidney Int. Suppl. 4, 45-52.
10. Barandon, L., Couffinhal, T., Ezan, J., Dufourcq, P., Costet, P., Alzieu, P., Leroux, L., Moreau, C., Dare, D. and Duplaa, C. (2003). Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation 108, 2282-2289.
11. Barandon, L., Dufourcq, P., Costet, P., Moreau, C., Allières, C., Daret, D., Dos Santos, P., Daniel Lamaziere, J.-M., Couffinhal, T. and Duplàa, C. (2005). Involvement of FrzA/sFRP-1 and the Wnt/frizzled pathway in ischemic preconditioning. Circ. Res. 96, 1299-1306.
12. Baurand, A., Zelarayan, L., Betney, R., Gehrke, C., Dunger, S., Noack, C., Busjahn, A., Huelsken, J., Taketo, M. M., Birchmeier, W. et al. (2007). Betacatenin downregulation is required for adaptive cardiac remodeling. Circ. Res. 100, 1353-1362.
13. Beltrami, A. P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., Kasahara, H., Rota, M., Musso, E., Urbanek, K. et al. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114, 763-776.
14. Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabe-Heider, F., Walsh, S., Zupicich, J., Alkass, K., Buchholz, B. A., Druid, H. et al. (2009). Evidence for cardiomyocyte renewal in humans. Science 324, 98-102.
15. Berk, B. C., Fujiwara, K. and Lehoux, S. (2007). ECM remodeling in hypertensive heart disease. J. Clin. Invest. 117, 568-575.
16. Blin, G., Nury, D., Stefanovic, S., Neri, T., Guillevic, O., Brinon, B., Bellamy, V., Rücker-Martin, C., Barbry, P., Bel, A. et al. (2010). A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J. Clin. Invest. 120, 1125-1139.
17. Bolli, R., Chugh, A. R., D’Amario, D., Loughran, J. H., Stoddard, M. F., Ikram, S., Beache, G. M., Wagner, S. G., Leri, A., Hosoda, T. et al. (2011). Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378, 1847-1857.
18. Bollini, S., Smart, N. and Riley, P. R. (2011). Resident cardiac progenitor cells: at the heart of regeneration. J. Mol. Cell. Cardiol. 50, 296-303.
19. Bouveret, R., Waardenberg, A. J., Schonrock, N., Ramialison, M., Doan, T., de Jong, D., Bondue, A., Kaur, G., Mohamed, S., Fonoudi, H. et al. (2015). NKX2-5 mutations causative for congenital heart disease retain functionality and are directed to hundreds of targets. eLife 4, 9014.
20. Briegel, K. J. and Joyner, A. L. (2001). Identification and characterization of Lbh, a novel conserved nuclear protein expressed during early limb and heart development. Dev. Biol. 233, 291-304.
21. Brown, R. D., Ambler, S. K., Mitchell, M. D. and Long, C. S. (2005). The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol. 45, 657-687.
22. Butler, T. L., Esposito, G., Blue, G. M., Cole, A. D., Costa, M. W., Waddell, L. B., Walizada, G., Sholler, G. F., Kirk, E. P., Feneley, M. et al. (2010). GATA4 mutations in 357 unrelated patients with congenital heart malformation. Genet. Test. Mol. Biomark. 14, 797-802.
23. Camelliti, P., Borg, T. K. and Kohl, P. (2005). Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 65, 40-51.
24. Caplan, A. I. (2008). All MSCs are pericytes? Cell Stem Cell 3, 229-230.
25. Chaudhry, H. W., Dashoush, N. H., Tang, H., Zhang, L., Wang, X., Wu, E. X. and Wolgemuth, D. J. (2004). Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium. J. Biol. Chem. 279, 35858-35866.
26. Chen, C.-W., Okada, M., Proto, J. D., Gao, X., Sekiya, N., Beckman, S. A., Corselli, M., Crisan, M., Saparov, A., Tobita, K. et al. (2013). Human pericytes for ischemic heart repair. Stem Cells 31, 305-316.
27. Chen, W. C. W., Baily, J. E., Corselli, M., Díaz, M. E., Sun, B., Xiang, G., Gray, G. A., Huard, J. and Péault, B. (2015). Human myocardial pericytes: multipotent mesodermal precursors exhibiting cardiac specificity. Stem Cells 33, 557-573.
28. Chong, J. J. H., Chandrakanthan, V., Xaymardan, M., Asli, N. S., Li, J., Ahmed, I., Heffernan, C., Menon, M. K., Scarlett, C. J., Rashidianfar, A. et al. (2011). Adult cardiac-resident MSC-like stem cells with a proepicardial origin. Cell Stem Cell 9, 527-540.
29. Chong, J. J. H., Reinecke, H., Iwata, M., Torok-Storb, B., Stempien-Otero, A. and Murry, C. E. (2013). Progenitor cells identified by PDGFR-alpha expression in the developing and diseased human heart. Stem Cells Dev. 22, 1932-1943.
30. Chong, J. J. H., Yang, X., Don, C. W., Minami, E., Liu, Y.-W., Weyers, J. J., Mahoney, W. M., Van Biber, B., Cook, S. M., Palpant, N. J. et al. (2014). Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273-277.
31. Daskalopoulos, E. P., Hermans, K. C. and Blankesteijn, W. M. (2014). Cardiac (myo)fibroblast: Novel strategies for its targeting following myocardial infarction. Curr. Pharm. Des. 20, 1987-2002.
32. Deb, A. (2014). Cell-cell interaction in the heart via Wnt/beta-catenin pathway after cardiac injury. Cardiovasc. Res. 102, 214-223.
33. Del Re, D. P., Yang, Y., Nakano, N., Cho, J., Zhai, P., Yamamoto, T., Zhang, N., Yabuta, N., Nojima, H., Pan, D. et al. (2013). Yes-associated protein isoform 1 (Yap1) promotes cardiomyocyte survival and growth to protect against myocardial ischemic injury. J. Biol. Chem. 288, 3977-3988.
34. D’Uva, G., Aharonov, A., Lauriola, M., Kain, D., Yahalom-Ronen, Y., Carvalho, S., Weisinger, K., Bassat, E., Rajchman, D., Yifa, O. et al. (2015). ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat. Cell Biol. 17, 627-638.
35. Ebmeier, S. and Horsley, V. (2015). Origin of fibrosing cells in systemic sclerosis. Curr. Opin. Rheumatol. 27, 555-562.
36. Epelman, S., Lavine, K. J., Beaudin, A. E., Sojka, D. K., Carrero, J. A., Calderon, B., Brija, T., Gautier, E. L., Ivanov, S., Satpathy, A. T. et al. (2014). Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 40, 91-104.
37. Feric, N. T. and Radisic, M. (2016). Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues. Adv. Drug Deliv. Rev. 96, 110-134.
38. Fu, J.-D., Stone, N. R., Liu, L., Spencer, C. I., Qian, L., Hayashi, Y., Delgado- Olguin, P., Ding, S., Bruneau, B. G. and Srivastava, D. (2013). Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Rep. 1, 235-247.
39. Furtado, M. B., Costa, M. W., Pranoto, E. A., Salimova, E., Pinto, A. R., Lam, N. T., Park, A., Snider, P., Chandran, A., Harvey, R. P. et al. (2014a). Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ. Res. 114, 1422-1434.
40. Furtado, M. B., Nim, H. T., Gould, J. A., Costa, M.W., Rosenthal, N. A. and Boyd, S. E. (2014b). Microarray profiling to analyse adult cardiac fibroblast identity. Genomics Data 2, 345-350.
41. Garg, V., Kathiriya, I. S., Barnes, R., Schluterman, M. K., King, I. N., Butler, C. A., Rothrock, C. R., Eapen, R. S., Hirayama-Yamada, K., Joo, K. et al. (2003). GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424, 443-447.
42. Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R. and Lemke, G. (1995). Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378, 390-394.
43. Granados-Riveron, J. T., Pope, M., Bu’Lock, F. A., Thornborough, C., Eason, J., Setchfield, K., Ketley, A., Kirk, E. P., Fatkin, D., Feneley, M. P. et al. (2012). Combined mutation screening of NKX2-5, GATA4, and TBX5 in congenital heart disease: multiple heterozygosity and novel mutations. Congenit. Heart Dis. 7, 151-159.
44. Guan, K. and Hasenfuss, G. (2013). Cardiac resident progenitor cells: evidence and functional significance. Eur. Heart J. 34, 2784-2787.
45. Haq, S., Michael, A., Andreucci, M., Bhattacharya, K., Dotto, P., Walters, B., Woodgett, J., Kilter, H. and Force, T. (2003). Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc. Natl. Acad. Sci. USA 100, 4610-4615.
46. Hassink, R. J., Pasumarthi, K. B., Nakajima, H., Rubart, M., Soonpaa, M. H., de la Riviere, A. B., Doevendans, P. A. and Field, L. J. (2008). Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction. Cardiovasc. Res. 78, 18-25.
47. Haudek, S. B., Xia, Y., Huebener, P., Lee, J. M., Carlson, S., Crawford, J. R., Pilling, D., Gomer, R. H., Trial, J., Frangogiannis, N. G. et al. (2006). Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc. Natl. Acad. Sci. USA 103, 18284-18289.
48. He, W., Zhang, L., Ni, A., Zhang, Z., Mirotsou, M., Mao, L., Pratt, R. E. and Dzau, V. J. (2010). Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc. Natl. Acad. Sci. USA 107, 21110-21115.
49. Ieda, M., Tsuchihashi, T., Ivey, K. N., Ross, R. S., Hong, T.-T., Shaw, R. M. and Srivastava, D. (2009). Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev. Cell 16, 233-244.
50. Ieda, M., Fu, J.-D., Delgado-Olguin, P., Vedantham, V., Hayashi, Y., Bruneau, B. G. and Srivastava, D. (2010). Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142, 375-386.
51. Kajstura, J., Gurusamy, N., Ogorek, B., Goichberg, P., Clavo-Rondon, C., Hosoda, T., D’Amario, D., Bardelli, S., Beltrami, A. P., Cesselli, D. et al. (2010). Myocyte turnover in the aging human heart. Circ. Res. 107, 1374-1386.
52. Kakkar, R. and Lee, R. T. (2010). Intramyocardial fibroblast myocyte communication. Circ. Res. 106, 47-57.
53. Kattman, S. J., Witty, A. D., Gagliardi, M., Dubois, N. C., Niapour, M., Hotta, A., Ellis, J. and Keller, G. (2011). Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8, 228-240.
54. Katz, T. C., Singh, M. K., Degenhardt, K., Rivera-Feliciano, J., Johnson, R. L., Epstein, J. A. and Tabin, C. J. (2012). Distinct compartments of the proepicardial organ give rise to coronary vascular endothelial cells. Dev. Cell 22, 639-650.
55. Kim, J., Shapiro, L. and Flynn, A. (2015). The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease. Pharmacol. Ther. 151, 8-15.
56. Kirk, E. P., Sunde, M., Costa, M. W., Rankin, S. A., Wolstein, O., Castro, M. L., Butler, T. L., Hyun, C., Guo, G., Otway, R. et al. (2007). Mutations in cardiac T-box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy. Am. J. Hum. Genet. 81, 280-291.
57. Kobayashi, K., Luo, M., Zhang, Y., Wilkes, D. C., Ge, G., Grieskamp, T., Yamada, C., Liu, T.-C., Huang, G., Basson, C. T. et al. (2009). Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat. Cell Biol. 11, 46-55.
58. Kohl, P. and Gourdie, R. G. (2014). Fibroblast–myocyte electrotonic coupling: does it occur in native cardiac tissue? J. Mol. Cell. Cardiol. 70, 37-46.
59. Krenning, G., Zeisberg, E. M. and Kalluri, R. (2010). The origin of fibroblasts and mechanism of cardiac fibrosis. J. Cell. Physiol. 225, 631-637.
60. Laeremans, H., Hackeng, T. M., van Zandvoort, M. A. M. J., Thijssen, V. L. J. L., Janssen, B. J. A., Ottenheijm, H. C. J., Smits, J. F. M. and Blankesteijn, W. M. (2011). Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation 124, 1626-1635.
61. Lai, D., Liu, X., Forrai, A., Wolstein, O., Michalicek, J., Ahmed, I., Garratt, A. N., Birchmeier, C., Zhou, M., Hartley, L. et al. (2010). Neuregulin 1 sustains the gene regulatory network in both trabecular and nontrabecular myocardium. Circ. Res. 107, 715-727.
62. Lajiness, J. D. and Conway, S. J. (2014). Origin, development, and differentiation of cardiac fibroblasts. J. Mol. Cell. Cardiol. 70, 2-8.
63. Laugwitz, K.-L., Moretti, A., Lam, J., Gruber, P., Chen, Y., Woodard, S., Lin, L.-Z., Cai, C.-L., Lu, M. M., Reth, M. et al. (2005). Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433, 647-653.
64. Leask, A. (2010). Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ. Res. 106, 1675-1680.
65. Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C. and Hauser, C. (1995). Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398.
66. Li, F., Wang, X., Capasso, J. M. and Gerdes, A. M. (1996). Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J. Mol. Cell. Cardiol. 28, 1737-1746.
67. Liao, H.-S., Kang, P. M., Nagashima, H., Yamasaki, N., Usheva, A., Ding, B., Lorell, B. H. and Izumo, S. (2001). Cardiac-specific overexpression of cyclindependent kinase 2 increases smaller mononuclear cardiomyocytes. Circ. Res. 88, 443-450.
68. Lin, Z., von Gise, A., Zhou, P., Gu, F., Ma, Q., Jiang, J., Yau, A. L., Buck, J. N., Gouin, K. A., van Gorp, P. R. R. et al. (2014). Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model. Circ. Res. 115, 354-363.
69. Malliaras, K., Li, T.-S., Luthringer, D., Terrovitis, J., Cheng, K., Chakravarty, T., Galang, G., Zhang, Y., Schoenhoff, F., Van Eyk, J. et al. (2012). Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125, 100-112.
70. Malliaras, K., Smith, R. R., Kanazawa, H., Yee, K., Seinfeld, J., Tseliou, E., Dawkins, J. F., Kreke, M., Cheng, K., Luthringer, D. et al. (2013). Validation of contrast-enhanced magnetic resonance imaging to monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial infarction. Circulation 128, 2764-2775.
71. Malliaras, K., Makkar, R. R., Smith, R. R., Cheng, K., Wu, E., Bonow, R. O., Marbán, L., Mendizabal, A., Cingolani, E., Johnston, P. V. et al. (2014). Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J. Am. Coll. Cardiol. 63, 110-122.
72. Matsushima, K., Suyama, T., Takenaka, C., Nishishita, N., Ikeda, K., Ikada, Y., Sawa, Y., Jakt, L. M., Mori, H. and Kawamata, S. (2010). Secreted frizzled related protein 4 reduces fibrosis scar size and ameliorates cardiac function after ischemic injury. Tissue Eng. A 16, 3329-3341.
73. Messina, E., De Angelis, L., Frati, G., Morrone, S., Chimenti, S., Fiordaliso, F., Salio, M., Battaglia, M., Latronico, M. V. G., Coletta, M. et al. (2004). Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 95, 911-921.
74. Misra, C., Sachan, N., McNally, C. R., Koenig, S. N., Nichols, H. A., Guggilam, A., Lucchesi, P. A., Pu, W. T., Srivastava, D. and Garg, V. (2012). Congenital heart disease–causing Gata4 mutation displays functional deficits in vivo. PLoS Genet. 8, e1002690.
75. Moore-Morris, T., Guimarães-Camboa, N., Banerjee, I., Zambon, A. C., Kisseleva, T., Velayoudon, A., Stallcup, W. B., Gu, Y., Dalton, N. D., Cedenilla, M. et al. (2014). Resident fibroblast lineages mediate pressure overload–induced cardiac fibrosis. J. Clin. Invest. 124, 2921-2934.
76. Nam, Y.-J., Song, K., Luo, X., Daniel, E., Lambeth, K., West, K., Hill, J. A., DiMaio, J. M., Baker, L. A., Bassel-Duby, R. et al. (2013a). Reprogramming of human fibroblasts toward a cardiac fate. Proc. Natl. Acad. Sci. USA 110, 5588-5593.
77. Nam, Y.-J., Song, K. and Olson, E. N. (2013b). Heart repair by cardiac reprogramming. Nat. Med. 19, 413-415.
78. Nam, Y.-J., Lubczyk, C., Bhakta, M., Zang, T., Fernandez-Perez, A., McAnally, J., Bassel-Duby, R., Olson, E. N. and Munshi, N. V. (2014). Induction of diverse cardiac cell types by reprogramming fibroblasts with cardiac transcription factors. Development 141, 4267-4278.
79. Noseda, M., Harada, M., McSweeney, S., Leja, T., Belian, E., Stuckey, D. J., Abreu Paiva, M. S., Habib, J., Macaulay, I., de Smith, A. J. et al. (2015). PDGFRalpha demarcates the cardiogenic clonogenic Sca1+ stem/progenitor cell in adult murine myocardium. Nat. Commun. 6, 6930.
80. Oh, H., Bradfute, S. B., Gallardo, T. D., Nakamura, T., Gaussin, V., Mishina, Y., Pocius, J., Michael, L. H., Behringer, R. R., Garry, D. J. et al. (2003). Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl. Acad. Sci. USA 100, 12313-12318.
81. Olivotto, I., Cecchi, F., Poggesi, C. and Yacoub, M. H. (2009). Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. Nat. Rev. Cardiol. 6, 317-321.
82. Pasumarthi, K. B. S., Nakajima, H., Nakajima, H. O., Soonpaa, M. H. and Field, L. J. (2005). Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ. Res. 96, 110-118.
83. Pinto, A. R., Paolicelli, R., Salimova, E., Gospocic, J., Slonimsky, E., Bilbao- Cortes, D., Godwin, J. W. and Rosenthal, N. A. (2012). An abundant tissue macrophage population in the adult murine heart with a distinct alternativelyactivated macrophage profile. PLoS ONE 7, e36814.
84. Pinto, A. R., Ilinykh, A., Ivey, M. J., Kuwabara, J. T., D’Antoni, M., Debuque, R. J., Chandran, A., Wang, L., Arora, K., Rosenthal, N. et al. (2015). Revisiting cardiac cellular composition. Circ.Res. (in press), pii: CIRCRESAHA.115.307778.
85. Polizzotti, B. D., Ganapathy, B., Walsh, S., Choudhury, S., Ammanamanchi, N., Bennett, D. G., dos Remedios, C. G., Haubner, B. J., Penninger, J. M. and Kühn, B. (2015). Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window. Sci. Transl. Med. 7, 281ra245.
86. Porrello, E. R., Mahmoud, A. I., Simpson, E., Hill, J. A., Richardson, J. A., Olson, E. N. and Sadek, H. A. (2011). Transient regenerative potential of the neonatal mouse heart. Science 331, 1078-1080.
87. Posch, M. G., Gramlich, M., Sunde, M., Schmitt, K. R., Lee, S. H. Y., Richter, S., Kersten, A., Perrot, A., Panek, A. N., Al Khatib, I. H. et al. (2010). A gain-offunction TBX20 mutation causes congenital atrial septal defects, patent foramen ovale and cardiac valve defects. J. Med. Genet. 47, 230-235.
88. Qian, L., Huang, Y., Spencer, C. I., Foley, A., Vedantham, V., Liu, L., Conway, S. J., Fu, J.-d. and Srivastava, D. (2012). In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485, 593-598.
89. Qian, L., Berry, E. C., Fu, J.-d., Ieda, M. and Srivastava, D. (2013). Reprogramming of mouse fibroblasts into cardiomyocyte-like cells in vitro. Nat. Protoc. 8, 1204-1215.
90. Qiao, Y., Wanyan, H., Xing, Q., Xie, W., Pang, S., Shan, J. and Yan, B. (2012). Genetic analysis of the TBX20 gene promoter region in patients with ventricular septal defects. Gene 500, 28-31.
91. Quaggin, S. E., Schwartz, L., Cui, S., Igarashi, P., Deimling, J., Post, M. and Rossant, J. (1999). The basic-helix-loop-helix protein pod1 is critically important for kidney and lung organogenesis. Development 126, 5771-5783.
92. Rosenbloom, J., Mendoza, F. A. and Jimenez, S. A. (2013). Strategies for antifibrotic therapies. Biochim. Biophys. Acta 1832, 1088-1103.
93. Santini, M. P., Tsao, L., Monassier, L., Theodoropoulos, C., Carter, J., Lara- Pezzi, E., Slonimsky, E., Salimova, E., Delafontaine, P., Song, Y. H. et al. (2007). Enhancing repair of the mammalian heart. Circ. Res. 100, 1732-1740.
94. Saraswati, S., Alfaro, M. P., Thorne, C. A., Atkinson, J., Lee, E. and Young, P. P. (2010). Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS ONE 5, e15521.
95. Schlesinger, J., Schueler, M., Grunert, M., Fischer, J. J., Zhang, Q., Krueger, T., Lange, M., Tönjes, M., Dunkel, I. and Sperling, S. R. (2011). The cardiac transcription network modulated by Gata4, Mef2a, Nkx2.5, Srf, histone modifications, and microRNAs. PLoS Genet. 7, e1001313.
96. Schuppan, D. (2015). Liver fibrosis: Common mechanisms and antifibrotic therapies. Clin. Res. Hepatol. Gastroenterol. 39, S51-S59.
97. Segura, A. M., Frazier, O. H. and Buja, L. M. (2014). Fibrosis and heart failure. Heart Fail. Rev. 19, 173-185.
98. Shapiro, S. D., Ranjan, A. K., Kawase, Y., Cheng, R. K., Kara, R. J., Bhattacharya, R., Guzman-Martinez, G., Sanz, J., Garcia, M. J. and Chaudhry, H. W. (2014). Cyclin A2 induces cardiac regeneration after myocardial infarction through cytokinesis of adult cardiomyocytes. Sci. Transl. Med. 6, 224ra27.
99. Smart, N., Bollini, S., Dubé, K. N., Vieira, J. M., Zhou, B., Davidson, S., Yellon, D., Riegler, J., Price, A. N., Lythgoe, M. F. et al. (2011). De novo cardiomyocytes from within the activated adult heart after injury. Nature 474, 640-644.
100. Smemo, S., Campos, L. C., Moskowitz, I. P., Krieger, J. E., Pereira, A. C. and Nobrega, M. A. (2012). Regulatory variation in a TBX5 enhancer leads to isolated congenital heart disease. Hum. Mol. Genet. 21, 3255-3263.
101. Smith, C. L., Baek, S. T., Sung, C. Y. and Tallquist, M. D. (2011). Epicardialderived cell epithelial-to-mesenchymal transition and fate specification require PDGF receptor signaling. Circ. Res. 108, e15-e26.
102. Soonpaa, M. H., Koh, G. Y., Pajak, L., Jing, S., Wang, H., Franklin, M. T., Kim, K. K. and Field, L. J. (1997). Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice. J. Clin. Invest. 99, 2644-2654.
103. Souders, C. A., Bowers, S. L. and Baudino, T. A. (2009). Cardiac fibroblast: the renaissance cell. Circ. Res. 105, 1164-1176.
104. Spagnolo, P., Tzouvelekis, A. and Maher, T. M. (2015). Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr. Opin. Pulm. Med. 21, 470-478.
105. Takahashi, K. and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676.
106. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872.
107. Takeda, N., Manabe, I., Uchino, Y., Eguchi, K., Matsumoto, S., Nishimura, S., Shindo, T., Sano, M., Otsu, K., Snider, P. et al. (2010). Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 120, 254-265.
108. The Lancet Editors (2014). Expression of concern: the SCIPIO trial. Lancet 383, 1279.
109. Troncoso, R., Ibarra, C., Vicencio, J. M., Jaimovich, E. and Lavandero, S. (2014). New insights into IGF-1 signaling in the heart. Trends Endocrinol. Metab. 25, 128-137.
110. van Amerongen, M. J., Bou-Gharios, G., Popa, E., van Ark, J., Petersen, A. H., van Dam, G. M., van Luyn, M. J. and Harmsen, M. C. (2008). Bone marrowderived myofibroblasts contribute functionally to scar formation after myocardial infarction. J. Pathol. 214, 377-386.
111. van Berlo, J. H., Kanisicak, O., Maillet, M., Vagnozzi, R. J., Karch, J., Lin, S.-C. J., Middleton, R. C., Marbán, E. and Molkentin, J. D. (2014). c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509, 337-341.
112. van Wijk, B., van den Berg, G., Abu-Issa, R., Barnett, P., van der Velden, S., Schmidt, M., Ruijter, J. M., Kirby, M. L., Moorman, A. F. M. and van den Hoff, M. J. B. (2009). Epicardium and myocardium separate from a common precursor pool by crosstalk between bone morphogenetic protein- and fibroblast growth factor-signaling pathways. Circ. Res. 105, 431-441.
113. Veerman, C. C., Kosmidis, G., Mummery, C. L., Casini, S., Verkerk, A. O. and Bellin, M. (2015). Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? Stem Cells Dev. 24, 1035-1052.
114. von Gise, A., Lin, Z., Schlegelmilch, K., Honor, L. B., Pan, G. M., Buck, J. N., Ma, Q., Ishiwata, T., Zhou, B., Camargo, F. D. et al. (2012). YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc. Natl. Acad. Sci. USA 109, 2394-2399.
115. Weber, K. T., Sun, Y., Bhattacharya, S. K., Ahokas, R. A. and Gerling, I. C. (2013). Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat. Rev. Cardiol. 10, 15-26.
116. Woo, Y. J., Panlilio, C. M., Cheng, R. K., Liao, G. P., Atluri, P., Hsu, V. M., Cohen, J. E. and Chaudhry, H. W. (2006). Myocardial Protection and Vascular Biology: therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation 114, I206-I213.
117. Wynn, T. A. (2008). Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210.
118. Xin, M., Kim, Y., Sutherland, L. B., Qi, X., McAnally, J., Schwartz, R. J., Richardson, J. A., Bassel-Duby, R. and Olson, E. N. (2011). Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci. Signal. 4, ra70.
119. Xin, M., Kim, Y., Sutherland, L. B., Murakami, M., Qi, X., McAnally, J., Porrello, E. R., Mahmoud, A. I., Tan, W., Shelton, J. M. et al. (2013). Hippo pathway effector Yap promotes cardiac regeneration. Proc. Natl. Acad. Sci. USA 110, 13839-13844.
120. Yacoub, M. H. and Terrovitis, J. (2013). CADUCEUS, SCIPIO, ALCADIA: cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving. Glob. Cardiol. Sci. Pract. 2013, 3.
121. Zeisberg, E. M. and Kalluri, R. (2010). Origins of cardiac fibroblasts. Circ. Res. 107, 1304-1312.
122. Zhou, B., Honor, L. B., Ma, Q., Oh, J.-H., Lin, R.-Z., Melero-Martin, J. M., von Gise, A., Zhou, P., Hu, T., He, L. et al. (2012). Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. J. Mol. Cell. Cardiol. 52, 43-47.
123. Zhou, H., Dickson, M. E., Kim, M. S., Bassel-Duby, R. and Olson, E. N. (2015). Akt1/protein kinase B enhances transcriptional reprogramming of fibroblasts to functional cardiomyocytes. Proc. Natl. Acad. Sci. USA 112, 11864-11869.